A
591.87
2.72 (0.46%)
| Penutupan Terdahulu | 589.15 |
| Buka | 582.96 |
| Jumlah Dagangan | 386,600 |
| Purata Dagangan (3B) | 289,661 |
| Modal Pasaran | 36,315,238,400 |
| Harga / Pendapatan (P/E TTM) | 46.31 |
| Harga / Pendapatan (P/E Ke hadapan) | 86.96 |
| Harga / Jualan (P/S) | 17.37 |
| Harga / Buku (P/B) | 6.47 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 |
| Margin Keuntungan | 37.05% |
| Margin Operasi (TTM) | 13.41% |
| EPS Cair (TTM) | 12.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 81.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.71% |
| Nisbah Semasa (MRQ) | 7.29 |
| Aliran Tunai Operasi (OCF TTM) | -82.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.39 M |
| Pulangan Atas Aset (ROA TTM) | -0.21% |
| Pulangan Atas Ekuiti (ROE TTM) | 17.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | argenx SE | Menaik | Menaik |
AISkor Stockmoo
1.6
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.63 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 56.76% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1,100.00 (Guggenheim, 85.85%) | Beli |
| Median | 704.00 (18.95%) | |
| Rendah | 680.00 (Baird, 14.89%) | Pegang |
| Purata | 751.89 (27.04%) | |
| Jumlah | 8 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 630.08 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 10 Mar 2025 | 1,100.00 (85.85%) | Beli | 571.00 |
| Baird | 04 Mar 2025 | 680.00 (14.89%) | Pegang | 621.25 |
| Citizens Capital Markets | 28 Feb 2025 | 701.00 (18.44%) | Beli | 624.67 |
| HC Wainwright & Co. | 28 Feb 2025 | 720.00 (21.65%) | Beli | 624.67 |
| 14 Jan 2025 | 717.00 (21.14%) | Beli | 665.60 | |
| Oppenheimer | 28 Feb 2025 | 704.00 (18.95%) | Beli | 624.67 |
| Wells Fargo | 28 Feb 2025 | 741.00 (25.20%) | Beli | 624.67 |
| JMP Securities | 14 Jan 2025 | 696.00 (17.59%) | Beli | 665.60 |
| Truist Securities | 14 Jan 2025 | 700.00 (18.27%) | Beli | 665.60 |
| Piper Sandler | 07 Jan 2025 | 725.00 (22.49%) | Beli | 648.62 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Mar 2025 | Pengumuman | argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting |
| 27 Feb 2025 | Pengumuman | argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update |
| 25 Feb 2025 | Pengumuman | argenx to Present at TD Cowen 45th Annual Healthcare Conference |
| 20 Feb 2025 | Pengumuman | argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 |
| 13 Jan 2025 | Pengumuman | argenx Highlights 2025 Strategic Priorities |
| 06 Jan 2025 | Pengumuman | argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |